250 related articles for article (PubMed ID: 10749682)
21. Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer.
Wu MH; Lohrbach KE; Olopade OI; Kokkinakis DM; Friedman HS; Dolan ME
Clin Cancer Res; 1999 Jan; 5(1):209-13. PubMed ID: 9918221
[TBL] [Abstract][Full Text] [Related]
22. Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling.
Gronemeyer T; Chidley C; Juillerat A; Heinis C; Johnsson K
Protein Eng Des Sel; 2006 Jul; 19(7):309-16. PubMed ID: 16638797
[TBL] [Abstract][Full Text] [Related]
23. Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine.
Edara S; Kanugula S; Goodtzova K; Pegg AE
Cancer Res; 1996 Dec; 56(24):5571-5. PubMed ID: 8971155
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice.
Ewesuedo RB; Wilson LR; Friedman HS; Moschel RC; Dolan ME
Cancer Chemother Pharmacol; 2001; 47(1):63-9. PubMed ID: 11221964
[TBL] [Abstract][Full Text] [Related]
25. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
[TBL] [Abstract][Full Text] [Related]
26. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Reese JS; Davis BM; Liu L; Gerson SL
Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
[TBL] [Abstract][Full Text] [Related]
28. Effect of alterations of key active site residues in O6-alkylguanine-DNA Alkyltransferase on its ability to modulate the genotoxicity of 1,2-dibromoethane.
Liu L; Watanabe K; Fang Q; Williams KM; Guengerich FP; Pegg AE
Chem Res Toxicol; 2007 Jan; 20(1):155-63. PubMed ID: 17226938
[TBL] [Abstract][Full Text] [Related]
29. Creation of human alkyltransferases resistant to O6-benzylguanine.
Christians FC; Dawson BJ; Coates MM; Loeb LA
Cancer Res; 1997 May; 57(10):2007-12. PubMed ID: 9157998
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterisation of the Drosophila melanogaster O6-alkylguanine-DNA alkyltransferase cDNA.
Kooistra R; Zonneveld JB; Watson AJ; Margison GP; Lohman PH; Pastink A
Nucleic Acids Res; 1999 Apr; 27(8):1795-801. PubMed ID: 10101186
[TBL] [Abstract][Full Text] [Related]
31. Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
Maze R; Kurpad C; Pegg AE; Erickson LC; Williams DA
J Pharmacol Exp Ther; 1999 Sep; 290(3):1467-74. PubMed ID: 10454526
[TBL] [Abstract][Full Text] [Related]
32. Depletion of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine in three-dimensional collagen cultures of normal human breast epithelial cells.
Hamdan MA; Guzman RC; Yang J; Beattie C; Mascharack P; Nandi S
Carcinogenesis; 1992 Oct; 13(10):1743-9. PubMed ID: 1423833
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of MGMT in the treatment of cancer.
Gerson SL
J Clin Oncol; 2002 May; 20(9):2388-99. PubMed ID: 11981013
[TBL] [Abstract][Full Text] [Related]
34. Expression of the inactive C145A mutant human O6-alkylguanine-DNA alkyltransferase in E.coli increases cell killing and mutations by N-methyl-N'-nitro-N-nitrosoguanidine.
Edara S; Kanugula S; Pegg AE
Carcinogenesis; 1999 Jan; 20(1):103-8. PubMed ID: 9934856
[TBL] [Abstract][Full Text] [Related]
35. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
36. Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O(6)-alkylguanine-DNA alkyltransferase.
Daniels DS; Tainer JA
Mutat Res; 2000 Aug; 460(3-4):151-63. PubMed ID: 10946226
[TBL] [Abstract][Full Text] [Related]
37. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Dolan ME; Posner M; Karrison T; Radosta J; Steinberg G; Bertucci D; Vujasin L; Ratain MJ
Clin Cancer Res; 2002 Aug; 8(8):2519-23. PubMed ID: 12171878
[TBL] [Abstract][Full Text] [Related]
38. Effect of O6-alkylguanine-DNA alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-N'-nitro-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts.
Lukash LL; Boldt J; Pegg AE; Dolan ME; Maher VM; McCormick JJ
Mutat Res; 1991; 250(1-2):397-409. PubMed ID: 1944354
[TBL] [Abstract][Full Text] [Related]
39. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
40. Engineering human DNA alkyltransferases for gene therapy using random sequence mutagenesis.
Encell LP; Coates MM; Loeb LA
Cancer Res; 1998 Mar; 58(5):1013-20. PubMed ID: 9500464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
